Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

European Journal of Cancer

Volumn 40, Issue 12, 2004, Pages 1878-1885

  Sung, Lillian ^a   Anderson, James R ^b   Donaldson, Sarah S ^c   Spunt, Sheri L ^d   Crist, William M ^e   Pappo, Alberto S ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e University of Missouri   (United States)

Author keywords

Failure; Relapse; Rhabdomyosarcoma; Second malignant neoplasm

Indexed keywords

ARTICLE; CANCER PATIENT; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; EVENT RELATED POTENTIAL; FEMALE; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; METASTASIS; PILOT STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; RHABDOMYOSARCOMA; RISK ASSESSMENT; SURVIVAL TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; SURVIVORS; TREATMENT FAILURE;

EID: 3843144251     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.04.005     Document Type: Article

References (28)

1. Crist W., Gehan E.A., Ragab A.H., et al. The Third Intergroup Rhabdomyosarcoma Study. J. Clin. Oncol. 13:1995;610-630
2. Pappo A.S., Shapiro D.N., Crist W.M., Maurer H.M. Biology and therapy of pediatric rhabdomyosarcoma. J. Clin. Oncol. 13:1995;2123-2139
3. Mertens A.C., Yasui Y., Neglia J.P., et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J. Clin. Oncol. 19:2001;3163-3172
4. Hudson M.M., Jones D., Boyett J., Sharp G.B., Pui C.H. Late mortality of long-term survivors of childhood cancer. J. Clin. Oncol. 15:1997;2205-2213
5. Hawkins M.M., Kingston J.E., Kinnier Wilson L.M. Late deaths after treatment for childhood cancer. Arch. Dis. Child. 65:1990;1356-1363
6. Nicholson H.S., Fears T.R., Byrne J. Death during adulthood in survivors of childhood and adolescent cancer. Cancer. 73:1994;3094-3102
7. Robertson C.M., Hawkins M.M., Kingston J.E. Late deaths and survival after childhood cancer: implications for cure. BMJ. 309:1994;162-166
8. Baker K.S., Anderson J.R., Link M.P., et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. J. Clin. Oncol. 18:2000;2427-2434
9. Pappo A.S., Anderson J.R., Crist W.M., et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J. Clin. Oncol. 17:1999;3487-3493
10. Greenwood M. The natural duration of cancer. Reports of public health and medical subjects. London; 1926
11. Zacharin M., Waters K., Chow C.W., Crock P., McKelvie P. Recurrent rhabdomyosarcoma after 25 years: a possible association with estrogen and progestogen therapy. J. Pediatr. Hematol. Oncol. 19:1997;477-481
12. Heyn R., Haeberlen V., Newton W.A., et al. Second malignant neoplasms in children treated for rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee. J. Clin. Oncol. 11:1993;262-270
13. Heyn R., Khan F., Ensign L.G., et al. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report. Med. Pediatr. Oncol. 23:1994;99-106
14. Scaradavou A., Heller G., Sklar C.A., Ren L., Ghavimi F. Second malignant neoplasms in long-term survivors of childhood rhabdomyosarcoma. Cancer. 76:1995;1860-1867
15. Raney R.B., Asmar L., Vassilopoulou-Sellin R., et al. Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: a descriptive report from the Intergroup Rhabdomyosarcoma Studies IRS-II and -III. IRS Group of the Children's Cancer Group and the Pediatric Oncology Group. Med. Pediatr. Oncol. 33:1999;362-371
16. Paulino A.C., Simon J.H., Zhen W., Wen B.C. Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma. Int. J. Radiat. Oncol. Biol. Phys. 48:2000;1489-1495
17. Strong L.C., Herson J., Osborne B.M., Sutow W.W. Risk of radiation-related subsequent malignant tumors in survivors of Ewing's sarcoma. J. Natl. Cancer Inst. 62:1979;1401-1406
18. Tucker M.A., D'Angio G.J., Boice J.D. Jr., et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N. Engl. J. Med. 317:1987;588-593
19. Kuttesch J.F. Jr., Wexler L.H., Marcus R.B., et al. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J. Clin. Oncol. 14:1996;2818-2825
20. Nicholson H.S., Mulvihill J.J., Byrne J. Late effects of therapy in adult survivors of osteosarcoma and Ewing's sarcoma. Med. Pediatr. Oncol. 20:1992;6-12
21. Smith L.M., Cox R.S., Donaldson S.S. Second cancers in long-term survivors of Ewing's sarcoma. Clin. Orthop. 1992;275-281
22. Gasparini M., Lombardi F., Ballerini E., et al. Long-term outcome of patients with monostotic Ewing's sarcoma treated with combined modality. Med. Pediatr. Oncol. 23:1994;406-412
23. Travis L.B., Curtis R.E., Hankey B.F., Fraumeni J.F. Jr. Second cancers in patients with Ewing's sarcoma. Med. Pediatr. Oncol. 22:1994;296-297
24. Dunst J., Ahrens S., Paulussen M., et al. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. Int. J. Radiat. Oncol. Biol. Phys. 42:1998;379-384
25. Hudson M.M., Poquette C.A., Lee J., et al. Increased mortality after successful treatment for Hodgkin's disease. J. Clin. Oncol. 16:1998;3592-3600
26. Crist W.M., Anderson J.R., Meza J.L., et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J. Clin. Oncol. 19:2001;3091-3102
27. Lipshultz S.E., Lipsitz S.R., Mone S.M., et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N. Engl. J. Med. 332:1995;1738-1743
28. Pui C.H., Ribeiro R.C., Hancock M.L., et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N. Engl. J. Med. 325:1991;1682-1687